A nurse in a mental health clinic is reviewing laboratory results for a client who has a prescription for risperidone. For which of the following findings should the nurse notify the provider?

To find out how many mL the nurse should administer for the total daily dose, we need to calculate the total daily dose and then convert it to mL using the available concentration.

The client is prescribed hydroxyzine 60 mg PO every 8 hours. To find the total daily dose, we can first calculate the dose per day and then convert it to mL.

Dose per day = Dose per dose interval x Number of doses per day

Dose per day = 60 mg x 3 (every 8 hours)

Dose per day = 180 mg per day

Now, we need to convert this dose to mL using the available concentration:

Concentration: 10 mg/5 mL

To find out how many mL for 180 mg, we can set up a proportion:

(10 mg / 5 mL) = (180 mg / x mL)

Cross-multiply:

10 mg * x mL = 5 mL * 180 mg

Now, solve for x (the number of mL):

x mL = (5 mL * 180 mg) / 10 mg

x mL = 900 mL / 10 mg

x mL = 90 mL

So, the nurse should administer 90 mL for the total daily dose.

A. Monitor the client's sodium levels:
This action is not directly related to the administration of olanzapine. Olanzapine does not typically affect sodium levels directly. Monitoring sodium levels is essential for some other medications or conditions, but it is not a specific consideration for olanzapine administration.

B. Evaluate the client's frequency of panic attacks:
Evaluating the frequency of panic attacks is not directly related to the administration of olanzapine. Olanzapine is an antipsychotic medication used to treat conditions like schizophrenia and bipolar disorder. It is not primarily indicated for the treatment of panic attacks. Monitoring panic attacks would be relevant if the client's primary concern was panic disorder, but it's not the priority in this scenario.

C. Inform the client that application site rash is common:
This information is not relevant to the administration of olanzapine in the form of an intramuscular injection. Application site rash is a concern for topical medications or transdermal patches, not for IM injections. Therefore, informing the client about application site rash is not necessary in this context.

D. Observe the client for 3 hours following the administration of medication:
This is the correct action. Olanzapine extended-release IM injection requires close observation for at least 3 hours after administration. This monitoring period is essential due to the potential risk of post-injection delirium/sedation syndrome, which can occur shortly after the injection. Monitoring allows for the early detection of any adverse reactions, ensuring the client's safety and well-being.